Latest news and press releases about BriaCell Therapeutics Corp. (BCTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer.
Price
| Price | $3.56 |
| Market Cap | $31M |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 1.06 |
| EV / EBITDA | -0.75 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -147.92% |
| Return on Invested Capital | -136.31% |
| Return on Assets | -113.23% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLR · ASBP · CRIS · CTXR · ENTO · HOTH · LPTX
Explore sector: Healthcare · Biotechnology
More sections of BCTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks